Vaccines targeting helper T cells for cancer immunotherapy

Current Opinion in Immunology

Volumn 47, Issue , 2017, Pages 85-92

  Melssen, Marit ^a   Slingluff, Craig L ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANYLGLUTAMINYLASPARAGINYLISOLEUCYLLEUCYLLEUCYLSERYLASPARAGINYLALANYLPROPYLLEUCYLGLYCYLPROPYLGLUTAMINYLPHENYLALANYLPROLINE; ARGINYLASPARAGINYLGLYCYLTYROSYLARGINYLALANYLLEUCYLMETHIONYLASPARTYLLYSYLSERYLLEUCYLHISTIDINYLVALYLGLYCYLTHREONYLGLUTAMINYLCYSTEINYLALANYLLEUCYLTHREONYLARGINYLARGININE; ASPARTYLTYROSYLSERYLTYROSYLLEUCYLGLUTAMINYLASPARTYLSERYLASPARTYLPROPYLASPARTYLSERYLPHENYLALANYLGLUTAMINYLASPARTIC ACID; CANCER VACCINE; GLUTAMYLALANYLARGINYLPROPYLALANYLLEUCYLLEUCYLTHREONYLSERYLARGINYLLEUCYLARGINYLPHENYLALANYLISOLEUCYLPROPYLLYSINE; GX 301; LEUCYLLEUCYLLYSYLTYROSYLARGINYLALANYLARGINYLGLUTAMYLPROPYLVALYLTHREONYLLYSYLALANYLGLUTAMIC ACID; LYSYLTHREONYLTRYPTOPHYLGLYCYLGLUTAMINYLTYROSYLTRYPTOPHYLGLUTAMINYLVALINE; PEPTIDE; PHENYLALANYLLEUCYLLEUCYLHISTIDINYLHISTIDINYLALANYLPHENYLALANYLVALYLASPARTYLSERYLISOLEUCYLPHENYLALANYLGLUTAMYLGLUTAMINYLTRYPTOPHYLLEUCYLGLUTAMINYLARGINYLHISTIDINYLARGINYLPROLINE; TERTOMOTIDE; THREONYLSERYLTYROSYLVALYLLYSYLVALYLLEUCYLHISTIDINYLHISTIDINYLMETHIONYLVALYLLYSYLISOLEUCYLSERYLGLYCINE; TRYPTOPHYLASPARAGINYLARGINYLGLUTAMINYLLEUCYLTYROSYLPROPYLGLUTAMYLTRYPTOPHYLTHREONYLGLUTAMYLALANYLGLUTAMINYLARGINYLLEUCYLASPARTIC ACID; TYROSYLMETHIONYLASPARTYLGLYCYLTHREONYLMETHIONYLSERYLGLUTAMINYLVALINE; UNCLASSIFIED DRUG; CD4 ANTIGEN; SUBUNIT VACCINE; TUMOR ANTIGEN;

ANTIGEN PRESENTATION; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL HOMING; CROSS PRESENTATION; EFFECTOR CELL; HELPER CELL; HUMAN; KIDNEY CARCINOMA; MALIGNANT NEOPLASM; MELANOMA; MEMORY T LYMPHOCYTE; NON SMALL CELL LUNG CANCER; NONHUMAN; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; T LYMPHOCYTE ACTIVATION; TH1 CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; ADOPTIVE IMMUNOTHERAPY; ANIMAL; IMMUNOLOGY; METABOLISM; NEOPLASM; PROCEDURES; TRANSPLANTATION;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4 ANTIGENS; CD8-POSITIVE T-LYMPHOCYTES; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; T-LYMPHOCYTES, HELPER-INDUCER; VACCINES, SUBUNIT;

EID: 85025693217     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2017.07.004     Document Type: Review

References (71)

1. Rosenberg, S.A., Yang, J.C., Restifo, N.P., Cancer immunotherapy: moving beyond current vaccines. Nat Med 10 (2004), 909–915.
2. Kim, H.J., Cantor, H., CD4 T-cell subsets and tumor immunity: the helpful and the not-so-helpful. Cancer Immunol Res 2 (2014), 91–98.
3. Kumai, T., Lee, S., Cho, H.I., Sultan, H., Kobayashi, H., Harabuchi, Y., Celis, E., Optimization of peptide vaccines to induce robust antitumor CD4 T-cell responses. Cancer Immunol Res 5 (2017), 72–83.
4. Spitzer, M.H., Carmi, Y., Reticker-Flynn, N.E., Kwek, S.S., Madhireddy, D., Martins, M.M., Gherardini, P.F., Prestwood, T.R., Chabon, J., Bendall, S.C., et al. Systemic immunity is required for effective cancer immunotherapy. Cell, 2017.
5. Kayaga, J., Souberbielle, B.E., Sheikh, N., Morrow, W.J., Scott-Taylor, T., Vile, R., Chong, H., Dalgleish, A.G., Anti-tumour activity against B16-F10 melanoma with a GM-CSF secreting allogeneic tumour cell vaccine. Gene Therapy 6 (1999), 1475–1481.
6. Hunder, N.N., Wallen, H., Cao, J., Hendricks, D.W., Reilly, J.Z., Rodmyre, R., Jungbluth, A., Gnjatic, S., Thompson, J.A., Yee, C., Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 358 (2008), 2698–2703.
7. Kahn, M., Sugawara, H., McGowan, P., Okuno, K., Nagoya, S., Hellstrom, K.E., Greenberg, P., CD4+ T cell clones specific for the human p97 melanoma-associated antigen can eradicate pulmonary metastases from a murine tumor expressing the p97 antigen. J Immunol 146 (1991), 3235–3241.
8. Xie, Y., Akpinarli, A., Maris, C., Hipkiss, E.L., Lane, M., Kwon, E.K., Muranski, P., Restifo, N.P., Antony, P.A., Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med 207 (2010), 651–667.
9. Quezada, S.A., Simpson, T.R., Peggs, K.S., Merghoub, T., Vider, J., Fan, X., Blasberg, R., Yagita, H., Muranski, P., Antony, P.A., et al. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts. J Exp Med 207 (2010), 637–650.
10. Redondo, M., Ruiz-Cabello, F., Concha, A., Hortas, M.L., Serrano, A., Morell, M., Garrido, F., Differential expression of MHC class II genes in lung tumour cell lines. Eur J Immunogenet 25 (1998), 385–391.
11. Ridge, J.P., Di, R.F., Matzinger, P., A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature 393 (1998), 474–478.
12. Bennett, S.R., Carbone, F.R., Karamalis, F., Flavell, R.A., Miller, J.F., Heath, W.R., Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393 (1998), 478–480.
13. Smith, C.M., Wilson, N.S., Waithman, J., Villadangos, J.A., Carbone, F.R., Heath, W.R., Belz, G.T., Cognate CD4(+) T cell licensing of dendritic cells in CD8(+) T cell immunity. Nat Immunol 5 (2004), 1143–1148.
14. Castellino, F., Huang, A.Y., Altan-Bonnet, G., Stoll, S., Scheinecker, C., Germain, R.N., Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature 440 (2006), 890–895.
15. Kumamoto, Y., Mattei, L.M., Sellers, S., Payne, G.W., Iwasaki, A., CD4+ T cells support cytotoxic T lymphocyte priming by controlling lymph node input. Proc Natl Acad Sci U S A 108 (2011), 8749–8754.
16. Ahrends, T., Babala, N., Xiao, Y., Yagita, H., van Eenennaam, H., Borst, J., CD27 agonism plus PD-1 blockade recapitulates CD4+ T-cell help in therapeutic anticancer vaccination. Cancer Res 76 (2016), 2921–2931.
17. Hassan, S.B., Sorensen, J.F., Olsen, B.N., Pedersen, A.E., Anti-CD40-mediated cancer immunotherapy: an update of recent and ongoing clinical trials. Immunopharmacol Immunotoxicol 36 (2014), 96–104.
18. Hung, K., Hayashi, R., Lafond-Walker, A., Lowenstein, C., Pardoll, D., Levitsky, H., The central role of CD4+ T-cells in the antitumor immune response. J Exp Med 188 (1998), 2357–2368.
19. Matsui, S., Ahlers, J.D., Vortmeyer, A.O., Terabe, M., Tsukui, T., Carbone, D.P., Liotta, L.A., Berzofsky, J.A., A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL. J Immunol 163 (1999), 184–193.
20. Schoenberger, S.P., Toes, R.E., van der Voort, E.I., Offringa, R., Melief, C.J., T-cell help for cytotoxic T lymphocytes is mediated by CD40–CD40L interactions. Nature 393 (1998), 480–483.
21. Giuntoli, R.L. 2nd, Lu, J., Kobayashi, H., Kennedy, R., Celis, E., Direct costimulation of tumor-reactive CTL by helper T cells potentiate their proliferation, survival, and effector function. Clin Cancer Res 8 (2002), 922–931.
22. Dengel, L.T., Norrod, A.G., Gregory, B.L., Clancy-Thompson, E., Burdick, M.D., Strieter, R.M., Slingluff, C.L. Jr., Mullins, D.W., Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma. J Immunother 33 (2010), 965–974.
23. Peng, W., Liu, C., Xu, C., Lou, Y., Chen, J., Yang, Y., Yagita, H., Overwijk, W.W., Lizee, G., Radvanyi, L., et al. PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines. Cancer Res 72 (2012), 5209–5218.
24. Wang, X., Michie, S.A., Xu, B., Suzuki, Y., Importance of IFN-gamma-mediated expression of endothelial VCAM-1 on recruitment of CD8+ T cells into the brain during chronic infection with Toxoplasma gondii. J Interferon Cytokine Res 27 (2007), 329–338.
25. Clancy-Thompson, E., King, L.K., Nunnley, L.D., Mullins, I.M., Slingluff, C.L. Jr., Mullins, D.W., Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T cells. Cancer Immunol Res 1 (2013), 332–339.
26. Bos, R., Sherman, L.A., CD4+ T-cell help in the tumor milieu is required for recruitment and cytolytic function of CD8+ T lymphocytes. Cancer Res 70 (2010), 8368–8377.
27. Nakanishi, Y., Lu, B., Gerard, C., Iwasaki, A., CD8(+) T lymphocyte mobilization to virus-infected tissue requires CD4(+) T-cell help. Nature 462 (2009), 510–513.
28. Harlin, H., Meng, Y., Peterson, A.C., Zha, Y., Tretiakova, M., Slingluff, C., McKee, M., Gajewski, T.F., Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment. Cancer Res 69 (2009), 3077–3085.
29. Dosset, M., Vauchy, C., Beziaud, L., Adotevi, O., Godet, Y., Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination. Oncoimmunology, 2, 2013, e23430.
30. Wong, S.B., Bos, R., Sherman, L.A., Tumor-specific CD4+ T cells render the tumor environment permissive for infiltration by low-avidity CD8+ T cells. J Immunol 180 (2008), 3122–3131.
31. Spranger, S., Spaapen, R.M., Zha, Y., Williams, J., Meng, Y., Ha, T.T., Gajewski, T.F., Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med, 5, 2013, 200ra116.
32. Cho, H.I., Lee, Y.R., Celis, E., Interferon gamma limits the effectiveness of melanoma peptide vaccines. Blood 117 (2011), 135–144.
33. Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal, 6, 2013, pl1.
34. Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, C.J., Heuer, M.L., Larsson, E., et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2 (2012), 401–404.
35. Matsuzaki, J., Tsuji, T., Luescher, I., Old, L.J., Shrikant, P., Gnjatic, S., Odunsi, K., Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells. Cancer Immunol Res 2 (2014), 341–350.
36. Matsuzaki, J., Tsuji, T., Luescher, I.F., Shiku, H., Mineno, J., Okamoto, S., Old, L.J., Shrikant, P., Gnjatic, S., Odunsi, K., Direct tumor recognition by a human CD4(+) T-cell subset potently mediates tumor growth inhibition and orchestrates anti-tumor immune responses. Sci Rep, 5, 2015, 14896.
37. Kennedy, R., Celis, E., Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev 222 (2008), 129–144.
38. Tateyama, M., Oyaizu, N., McCloskey, T.W., Than, S., Pahwa, S., CD4 T lymphocytes are primed to express Fas ligand by CD4 cross-linking and to contribute to CD8 T-cell apoptosis via Fas/FasL death signaling pathway. Blood 96 (2000), 195–202.
39. Qin, Z., Blankenstein, T., CD4+ T cell – mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN gamma receptor expression by nonhematopoietic cells. Immunity 12 (2000), 677–686.
40. Zanetti, M., Tapping CD4 T cells for cancer immunotherapy: the choice of personalized genomics. J Immunol 194 (2015), 2049–2056.
41. Buller, R.M., Holmes, K.L., Hugin, A., Frederickson, T.N., Morse, H.C. 3rd, Induction of cytotoxic T-cell responses in vivo in the absence of CD4 helper cells. Nature 328 (1987), 77–79.
42. Wu, Y., Liu, Y., Viral induction of co-stimulatory activity on antigen-presenting cells bypasses the need for CD4+ T-cell help in CD8+ T-cell responses. Curr Biol 4 (1994), 499–505.
43. Bevan, M.J., Helping the CD8(+) T-cell response. Nat Rev Immunol 4 (2004), 595–602.
44. Sun, J.C., Bevan, M.J., Cutting edge: long-lived CD8 memory and protective immunity in the absence of CD40 expression on CD8 T cells. J Immunol 172 (2004), 3385–3389.
45. Laidlaw, B.J., Zhang, N., Marshall, H.D., Staron, M.M., Guan, T., Hu, Y., Cauley, L.S., Craft, J., Kaech, S.M., CD4+ T cell help guides formation of CD103+ lung-resident memory CD8+ T cells during influenza viral infection. Immunity 41 (2014), 633–645.
46. Janssen, E.M., Droin, N.M., Lemmens, E.E., Pinkoski, M.J., Bensinger, S.J., Ehst, B.D., Griffith, T.S., Green, D.R., Schoenberger, S.P., CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature 434 (2005), 88–93.
47. Datta, J., Fracol, M., McMillan, M.T., Berk, E., Xu, S., Goodman, N., Lewis, D.A., DeMichele, A., Czerniecki, B.J., Association of depressed anti-HER2 T-helper type 1 response with recurrence in patients with completely treated HER2-positive breast cancer: role for immune monitoring. JAMA Oncol 2 (2016), 242–246.
48. Koski, G.K., Koldovsky, U., Xu, S., Mick, R., Sharma, A., Fitzpatrick, E., Weinstein, S., Nisenbaum, H., Levine, B.L., Fox, K., et al. A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer. J Immunother 35 (2012), 54–65.
49. Sharma, A., Koldovsky, U., Xu, S., Mick, R., Roses, R., Fitzpatrick, E., Weinstein, S., Nisenbaum, H., Levine, B.L., Fox, K., et al. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ. Cancer 118 (2012), 4354–4362.
50. Lowenfeld, L., Mick, R., Datta, J., Xu, S., Fitzpatrick, E., Fisher, C.S., Fox, K.R., DeMichele, A., Zhang, P., Weinstein, S., et al. Dendritic cell vaccination enhances immune responses and induces regression of HER2pos DCIS independent of route: results of randomized selection design trial. Clin Cancer Res, 2016.
51. Staff, C., Mozaffari, F., Frodin, J.E., Mellstedt, H., Liljefors, M., Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients. Int J Oncol 45 (2014), 1293–1303.
52. Hansen, G.L., Gaudernack, G., Brunsvig, P.F., Cvancarova, M., Kyte, J.A., Immunological factors influencing clinical outcome in lung cancer patients after telomerase peptide vaccination. Cancer Immunol Immunother 64 (2015), 1609–1621.
53. Fenoglio, D., Traverso, P., Parodi, A., Tomasello, L., Negrini, S., Kalli, F., Battaglia, F., Ferrera, F., Sciallero, S., Murdaca, G., et al. A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer. Cancer Immunol Immunother 62 (2013), 1041–1052.
54. Dosset, M., Godet, Y., Vauchy, C., Beziaud, L., Lone, Y.C., Sedlik, C., Liard, C., Levionnois, E., Clerc, B., Sandoval, F., et al. Universal cancer peptide-based therapeutic vaccine breaks tolerance against telomerase and eradicates established tumor. Clin Cancer Res 18 (2012), 6284–6295.
55. Middleton, G., Silcocks, P., Cox, T., Valle, J., Wadsley, J., Propper, D., Coxon, F., Ross, P., Madhusudan, S., Roques, T., et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. Lancet Oncol 15 (2014), 829–840.
56. Aarntzen, E.H., De Vries, I.J., Lesterhuis, W.J., Schuurhuis, D., Jacobs, J.F., Bol, K., Schreibelt, G., Mus, R., De Wilt, J.H., Haanen, J.B., et al. Targeting CD4(+) T-helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer Res 73 (2013), 19–29.
57. Slingluff, C.L. Jr., Petroni, G.R., Olson, W., Czarkowski, A.R., Grosh, W.W., Smolkin, M., Chianese-Bullock, K.A., Neese, P.Y., Deacon, D.H., Nail, C.J., et al. Helper T cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens. J Clin Oncol 26 (2008), 4973–4980.
58. Slingluff, C.L. Jr., Petroni, G.R., Chianese-Bullock, K.A., Smolkin, M.E., Ross, M.I., Haas, N.B., von Mehren, M., Grosh, W.W., Randomized multicenter trial of the effects of melanoma-associated helper peptides and cyclophosphamide on the immunogenicity of a multipeptide melanoma vaccine. J Clin Oncol 29 (2011), 2924–2932.
59. Slingluff, C.L. Jr., Lee, S., Zhao, F., Chianese-Bullock, K.A., Olson, W.C., Butterfield, L.H., Whiteside, T.L., Leming, P.D., Kirkwood, J.M., A randomized phase II trial of multiepitope vaccination with melanoma peptides for cytotoxic T cells and helper T cells for patients with metastatic melanoma (E1602). Clin Cancer Res 19 (2013), 4228–4238.
60. Dillon, P.M., Olson, W.C., Czarkowski, A., Petroni, G.R., Smolkin, M., Grosh, W.W., Chianese-Bullock, K.A., Deacon, D.H., Slingluff, C.L. Jr., A melanoma helper peptide vaccine increases Th1 cytokine production by leukocytes in peripheral blood and immunized lymph nodes. J Immunother Cancer, 2, 2014, 23.
61. Hu, Y., Kim, H., Blackwell, C.M., Slingluff, C.L. Jr., Long-term outcomes of helper peptide vaccination for metastatic melanoma. Ann Surg 262 (2015), 456–464 (discussion 462-454).
62. Hu, Y., Petroni, G.R., Olson, W.C., Czarkowski, A., Smolkin, M.E., Grosh, W.W., Chianese-Bullock, K.A., Slingluff, C.L. Jr., Immunologic hierarchy, class II MHC promiscuity, and epitope spreading of a melanoma helper peptide vaccine. Cancer Immunol Immunother 63 (2014), 779–786.
63. Reed, C.M., Cresce, N.D., Mauldin, I.S., Slingluff, C.L. Jr., Olson, W.C., Vaccination with melanoma helper peptides induces antibody responses associated with improved overall survival. Clin Cancer Res 21 (2015), 3879–3887.
64. Kenter, G.G., Welters, M.J., Valentijn, A.R., Lowik, M.J., B-vdM, D.M., Vloon, A.P., Essahsah, F., Fathers, L.M., Offringa, R., Drijfhout, J.W., et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 361 (2009), 1838–1847.
65. Tsuji, T., Sabbatini, P., Jungbluth, A.A., Ritter, E., Pan, L., Ritter, G., Ferran, L., Spriggs, D., Salazar, A.M., Gnjatic, S., Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial. Cancer Immunol Res 1 (2013), 340–350.
66. Cohen, C.J., Gartner, J.J., Horovitz-Fried, M., Shamalov, K., Trebska-McGowan, K., Bliskovsky, V.V., Parkhurst, M.R., Ankri, C., Prickett, T.D., Crystal, J.S., et al. Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest 125 (2015), 3981–3991.
67. Carreno, B.M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A.A., Ly, A., Lie, W.R., Hildebrand, W.H., Mardis, E.R., et al. Cancer immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells. Science 348 (2015), 803–808.
68. Hailemichael, Y., Dai, Z., Jaffarzad, N., Ye, Y., Medina, M.A., Huang, X.F., Dorta-Estremera, S.M., Greeley, N.R., Nitti, G., Peng, W., et al. Persistent antigen at vaccination sites induces tumor-specific CD8(+) T cell sequestration, dysfunction and deletion. Nat Med 19 (2013), 465–472.
69. Cho, H.I., Celis, E., Optimized peptide vaccines eliciting extensive CD8 T-cell responses with therapeutic antitumor effects. Cancer Res 69 (2009), 9012–9019.
70. Reinhardt, R.L., Bullard, D.C., Weaver, C.T., Jenkins, M.K., Preferential accumulation of antigen-specific effector CD4 T cells at an antigen injection site involves CD62E-dependent migration but not local proliferation. J Exp Med 197 (2003), 751–762.
71. Diefenbach, C.S., Gnjatic, S., Sabbatini, P., Aghajanian, C., Hensley, M.L., Spriggs, D.R., Iasonos, A., Lee, H., Dupont, B., Pezzulli, S., et al. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin Cancer Res 14 (2008), 2740–2748.